OakChart

Xenon Pharmaceuticals Inc

XENEHealthcare·Biotechnology·Canada·Mid·NASD·Nov 11 • 8:59 AM ET

41.38-0.01 (-0.02%)
2026-11-11 15:21 CET
Market cap
4,008.22 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-428.73 USD m
Free cash flow, TTM
-351.79 USD m
EPS diluted, TTM
-4.70
P/E
-
Compare

Price

XENE against its 20, 50 and 200-day averages
2050200beat
40.0050.0060.0070.009.0M17.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26XENEclose 41.3820-day 37.2650-day 41.90200-day 52.2841.38

43.0% under 72.66 on 9 Jul 2026. Last 15 sessions, 18.8% high to low

Profile

XENE
52-week range, 20% of the way up
33.3872.66

Xenon Pharmaceuticals, Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

IndexRUT
Employees370
IPONov 05, 2014
Beta0.07
ATR, 14d1.45
Rel volume0.01
Short float8.03%
Insider own5.26%
Inst own109.13%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap4.07B
Enterprise Value3.12B
Income-428.73M
Sales0.00M
Book/sh11.67
Cash/sh9.67
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees370
IPONov 05, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.55
P/C4.28
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio21.19
Current Ratio21.19
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.70
EPS next Y-4.61
EPS next Q-1.14
EPS this Y-4.70%
EPS next Y-1.00%
EPS next 5Y8.00%
EPS past 3/5Y-28.36% -40.02%
Sales past 3/5Y-7.36% -25.26%
EPS Y/Y TTM-21.09%
Sales Y/Y TTM-100.00%
EPS Q/Q3.50%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.1.89% -

Ownership

Insider Own5.26%
Insider Trans0.50%
Inst Own109.13%
Inst Trans2.84%
ROA-47.43%
ROE-50.27%
ROIC-37.24%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2011.07%
SMA50-1.23%
SMA200-20.85%
Trades-

Technical

Shs Outstand98.28M
Shs Float91.74M
Short Float8.03%
Short Ratio4.60
Short Interest7.36M
52W High72.66 -43.05%
52W Low33.38 23.97%
Volatility4.32% 3.65%
ATR (14)1.45
RSI (14)60.44
Beta0.07
Rel Volume0.01
Avg Volume1.60M
Volume982

Performance

Perf Week5.59%
Perf Month20.22%
Perf Quarter-35.58%
Perf Half Y-25.95%
Perf YTD-7.68%
Perf Year3.66%
Perf 3Y43.53%
Perf 5Y30.58%
Perf 10Y430.51%
Recom1.17
Target Price71.69
Prev Close41.39
Price41.38
Change %-0.02%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 06, 2026ResumedGGuggenheimBuy$73+76.4%
Sep 18, 2026DowngradeDDeutsche BankBuy → Hold$46+11.2%
Feb 24, 2026InitiatedWWolfe ResearchOutperform$60+45.0%
Sep 03, 2025ResumedWWells FargoOverweight$48+16.0%
May 07, 2025InitiatedCChardan Capital MarketsBuy$55+32.9%
Feb 11, 2025InitiatedDDeutsche BankBuy$67+61.9%
Oct 10, 2024ResumedRRaymond JamesOutperform$50+20.8%
Oct 01, 2024InitiatedHH.C. WainwrightBuy$53+28.1%
Jan 04, 2024InitiatedCCitigroupBuy$62+49.8%
Dec 08, 2023InitiatedRRobert W. BairdOutperform$63+52.2%

Peers

Mkt cap
TickerCompanyMkt cap
BHVNBiohaven Ltd2.35B
PRAXPraxis Precision Medicines Inc9.49B
RAPPRapport Therapeutics Inc1.52B
JAZZJazz Pharmaceuticals plc15.71B
DRUGBright Minds Biosciences Inc223.03M
STOKStoke Therapeutics Inc1.78B
OVIDOvid Therapeutics Inc537.07M
AXSMAxsome Therapeutics Inc7.47B
SUPNSupernus Inc5.97B
NBIXNeurocrine Biosciences Inc17.14B

Insider trading

latest 14 of 36
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Kelly Thomas PatrickChief Financial OfficerSep 30 '26Buy37.3215,000559,74015,000Oct 01 09:20 AM
MORTIMER IANPRESIDENT & CEOSep 30 '26Buy37.3830,0001,121,40049,923Oct 01 09:19 AM
Svoronos DawnDirectorSep 01 '26Option Exercise8.155,14441,92431,373Sep 03 08:26 PM
KENNEY CHRISTOPHER JOHNChief Medical OfficerAug 28 '26Sale60.257,068425,8292Aug 31 09:59 PM
CHRISTOPHER KENNEYOfficerAug 28 '26Proposed Sale61.937,068437,721Aug 28 04:25 PM
GANNON STEVENDirectorAug 11 '26Sale64.0610,000640,5501,870Aug 13 04:33 PM
STEVEN GANNONDirectorAug 11 '26Proposed Sale64.0610,000640,553Aug 13 04:30 PM
PATOU GARYDirectorJun 05 '26Sale53.141,32270,25124,896Jun 08 09:19 PM
Cannon GillianDirectorJun 05 '26Sale53.141,19063,2371,455Jun 08 09:19 PM
GILLIAN CANNONDirectorJun 05 '26Proposed Sale52.991,19063,058Jun 05 04:32 PM
GARY PATOUDirectorJun 05 '26Proposed Sale52.991,32270,053Jun 05 04:32 PM
GANNON STEVENDirectorMay 12 '26Option Exercise7.383,50025,83010,641May 13 09:40 PM
KENNEY CHRISTOPHER JOHNChief Medical OfficerMar 13 '26Sale55.231,41077,8677,069Mar 13 08:16 PM
DiFabio AndreaChief Legal OfficerMar 13 '26Sale55.231,34274,1127,301Mar 13 08:16 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
TCAFT. Rowe Price Capital Appreciation Equity ETFAUM: 7.62B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SPDWState Street SPDR Portfolio Developed World ex-US ETFAUM: 41.64B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
TMSLT. Rowe Price Small-Mid Cap ETFAUM: 3.28B

News

latest 14 of 206
  • Xenon's Narrow Per-Share Beat Masks A Wider Loss As A Psychiatry Safety Pause Overshadows The On-Time Azetukalner NDA (Earnings Whispers)
  • Xenon Pharmaceuticals: Q3 Earnings Snapshot (Associated Press)
  • Xenon Reports Q3 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Xenon to Present at Upcoming Investor Conferences (GlobeNewswire)
  • Xenon's NDA Filing Status Takes Center Stage After A 40% Slide Despite Upbeat Guidance (Earnings Whispers)
  • Loading…
  • Xenon to Report Q3 2026 Financial Results on November 9, 2026 (GlobeNewswire)
  • Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain (GlobeNewswire)
  • Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging (Barrons.com)
  • Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Xenons Insider Buying Tops $1.6M XENE Stock Heads For Best Day In Over Month (Stocktwits)
  • Ian Mortimer Receives the 2026 Bloom Burton Award (TMX Newsfile)
  • Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors (TMX Newsfile)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-1.110-1.131-1.1100.000.0016
2026Q22026-08-06-1.110-1.142-1.1120.001.6718
2026Q12026-05-07-1.170-1.180-1.1710.001.3618
2025Q42026-02-26-1.310-1.192-1.3140.000.0018
2025Q32025-11-03-1.150-1.152-1.1470.000.0018
2025Q22025-08-11-1.070-0.987-1.0730.000.0019
2025Q12025-05-12-0.830-0.896-0.8277.502.7118
2024Q42025-02-27-0.840-0.861-0.8380.000.3617
2024Q32024-11-12-0.810-0.816-0.8060.000.0017
2024Q22024-08-08-0.750-0.700-0.7460.000.0015
2024Q12024-05-09-0.620-0.664-0.6180.000.0016
2023Q42024-02-29-0.640-0.759-0.6400.002.3017
2023Q32023-11-08-0.730-0.774-0.7340.001.5615
2023Q22023-08-09-0.720-0.697-0.7210.000.4615
2023Q12023-05-09-0.630-0.621-0.6350.000.6215
2022Q42023-03-01-0.570-0.585-0.5700.002.9115

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.540-1.630-1.5436.833.50
2020FY-0.810-0.871-0.81132.1730.22
2021FY-1.770-1.658-1.76718.4420.72
2022FY-2.060-2.086-2.0649.4312.16
2023FY-2.730-2.827-2.7270.002.20
2024FY-3.010-3.097-3.0080.000.31
2025FY-4.360-4.247-4.3607.507.58
2026FY--4.565--1.44
2027FY--4.610--27.82
2028FY--3.395--211.5
2029FY-0.108--634.85
2030FY-3.067--1,007

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-108001.580.007.61
2026Q4S2026-11-098001.580.007.61
2026Q4S2026-10-298001.580.007.61
2026Q4S2026-08-079001.400.007.61
2026Q4S2026-07-229001.400.007.61
2026Q4S2026-06-149011.400.007.61
2026Q4S2026-06-0710011.260.007.61
2026Q4S2026-05-0811011.150.007.61
2026Q4S2026-03-2110003.260.0025.00
2026Q4S2026-03-0611002.960.0025.00
2026Q4S2026-03-0510003.260.0025.00
2026Q4S2026-02-279003.620.0025.00
2026Q4S2026-02-207000.000.000.00
2026Q4S2025-11-116000.000.000.00

Estimate history

EPS, annual-1.72-1.628-1.543-0.811-1.767-2.064-2.727-3.008-4.365-4.7036
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.806-0.838-0.827-1.073-1.147-1.314-1.171-1.112-1.107
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.31106.82932.16618.4379.434007.50
Period201720182019202020212022202320242025TTM
Sales, quarterly007.5000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual17.99825.75128.13935.01251.63562.58875.37176.41680.01198.275
Period201720182019202020212022202320242025MRQ
Shares, quarterly75.79476.41676.58676.9477.1280.01196.62496.75398.275
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.007.500.000.009.4318.4432.176.830.00
Cost of Goods Sold Incl. D&A2.322.542.563.54----0.59
Gross Profit-2.324.96-2.56-3.54-----0.59
Selling, General and Administrative Excl. Other463.00378.03276.74210.51136.9596.5262.8249.2231.45
Research and Development368.76298.40207.83167.51105.7775.4650.5238.8523.63
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-465.32-373.07-279.30-214.05-129.14-78.99-31.30-42.82-32.04
Interest Expense0.000.000.000.000.000.000.481.431.39
Unusual Expense0.000.000.00-3.552.930.720.990.001.60
Net Income Before Taxes-429.51-344.89-238.42-182.69-125.26-78.89-29.09-41.62-34.52
Income Taxes-0.781.02-4.09-0.290.12-0.01-0.26-0.02-0.02
Consolidated Net Income-428.73-345.91-234.33-182.39-125.37-78.88-28.84-41.60-34.50
Net Income From Continuing Operations-428.73-345.91-234.33-182.39-125.37-78.88-28.84-41.60-34.50
Net Income-428.73-345.91-234.33-182.39-124.94-77.09-28.01-40.03-31.62
EPS (Recurring)-4.30-4.36-3.01-2.76-2.03-1.76-0.79-1.54-1.57
EPS (Basic, Before Extraordinaries)-4.70-4.36-3.01-2.73-2.06-1.77-0.81-1.54-1.63
EPS (Diluted)-4.70-4.36-3.01-2.73-2.06-1.77-0.81-1.54-1.63
EBITDA-463.00-370.53-276.74-210.51-127.52-78.09-30.66-42.39-31.45
Non-Operating Income (Expense)35.8128.1840.8827.826.820.823.682.640.52
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense50.7942.4336.5225.5716.107.664.172.162.03
Price To Sales Ratio-473.62--253.0473.9216.5249.80-
Gross Margin-66.09-------
Operating Margin--4,974.27---1,368.91-428.45-97.31-627.02-
Net Margin--4,612.13---1,324.32-418.11-87.09-586.13-
Shares Outstanding98.2880.0176.4275.3762.5951.6335.0128.1425.75
Market Capitalization4,008.224,008.222,988.593,403.432,466.111,611.65538.41339.14159.26

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.007.500.00
Cost of Goods Sold Incl. D&A0.560.560.590.610.640.630.660.63
Gross Profit-0.56-0.56-0.59-0.61-0.64-0.636.84-0.63
Selling, General and Administrative Excl. Other119.51122.60111.74109.1695.7093.6079.5876.84
Research and Development95.0898.6787.9287.0976.4174.3560.5458.84
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-120.07-123.16-112.33-109.77-96.34-94.23-72.74-77.48
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-108.59-111.32-104.87-104.72-90.22-85.33-64.62-69.53
Income Taxes1.84-0.59-2.570.540.68-0.630.43-3.85
Consolidated Net Income-110.44-110.74-102.30-105.26-90.90-84.71-65.05-65.69
Net Income From Continuing Operations-110.44-110.74-102.30-105.26-90.90-84.71-65.05-65.69
Net Income-110.44-110.74-102.30-105.26-90.90-84.71-65.05-65.69
EPS (Recurring)-1.11-1.11-1.17-1.31-1.15-1.07-0.83-0.84
EPS (Basic, Before Extraordinaries)-1.11-1.11-1.17-1.31-1.15-1.07-0.83-0.84
EPS (Diluted)-1.11-1.11-1.17-1.31-1.15-1.07-0.83-0.84
EBITDA-119.50-122.60-111.74-109.16-95.69-93.60-72.08-76.84
Non-Operating Income (Expense)11.4811.837.465.046.128.908.127.94
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense13.0713.2213.3511.1510.839.629.629.79
Price To Sales Ratio---478.83424.24329.50352.00-
Gross Margin------91.21-
Operating Margin-------969.84-
Net Margin-------867.29-
Shares Outstanding98.2896.7596.6280.0177.1276.9476.5976.42
Market Capitalization4,008.225,834.745,549.093,463.473,095.802,401.762,568.012,988.59

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments548.89626.90638.08592.09551.77177.00141.36119.3143.67
Short Term Receivables1.371.470.870.992.771.820.810.150.44
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets10.396.896.017.224.482.962.691.880.72
Total Current Assets560.65635.26644.96600.30559.02181.78144.87121.3344.82
Net Property, Plant & Equipment15.3518.2218.8516.9112.526.882.590.991.07
Total Investments and Advances37.15127.50292.79128.680.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets361.37278.620.800.510.470.520.240.10-
Other Assets7.157.507.407.750.000.000.000.000.23
Total Assets981.671,067.09964.80754.15572.01189.19147.70122.4346.12
Short Term Debt Incl. Current Port. of LT Debt1.531.371.300.490.600.274.820.000.70
Accounts Payable3.885.078.608.493.823.042.470.671.25
Income Tax Payable0.31--------
Other Current Liabilities36.0629.1517.3813.729.8911.4736.093.452.13
Total Current Liabilities41.7935.5927.2722.7014.3214.7843.384.124.08
Long Term Debt6.417.659.609.957.653.0511.6315.016.10
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities348.51268.95-------
Other Liabilities3.200.000.000.000.000.000.710.000.00
Total Liabilities399.91312.1936.8832.6521.9717.8355.7219.1310.19
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.007.737.737.737.730.00
Common Equity581.76754.90927.92721.50542.30163.6284.2595.5635.93
Total Shareholders Equity581.76754.90927.92721.50550.03171.3591.98103.3035.93
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity581.76754.90927.92721.50550.03171.3591.98103.3035.93
Total Liabilities & Stockholders Equity981.671,067.09964.80754.15572.01189.19147.70122.4346.12
Book Value Per Share7.279.8812.3111.5310.504.672.993.712.00
Tangible Book Value Per Share7.279.8812.3111.5310.504.672.993.712.00
Full-Time Employees3703272592131531291049281
Price to Book Ratio3.553.724.703.272.973.294.381.701.17
Return on Assets-33.77-23.07-21.22-18.91-20.73-17.12-30.80-40.93-54.05
Return on Equity-51.76-27.85-22.12-19.72-21.87-21.90-42.60-49.55-61.51
Return on Invested Capital-58.81-30.73-19.45-17.14-14.14-16.53-40.15-29.16-73.04
Quick Ratio13.4217.8523.6526.4439.0312.303.3429.4610.98
Current Ratio13.4217.8523.6526.4439.0312.303.3429.4610.98

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-422.40-345.91-234.33-182.39-125.37-78.88-28.84-41.60-34.50
Depreciation2.282.542.563.541.620.910.640.430.59
Other Funds (Non Cash)59.9863.0953.5328.1826.0411.066.443.15-0.84
Funds from Operations-363.80-283.48-187.10-150.96-97.75-66.86-22.04-38.15-34.86
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital13.004.365.715.64-0.68-2.65-26.0933.520.14
Cash from Operating Activities-350.79-279.12-181.39-145.33-98.43-69.50-48.12-4.63-34.72
Capital Expenditures-1.00-0.80-3.08-5.62-2.89-2.05-2.64-1.24-0.51
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-616.43218.80168.08-111.55-293.11-244.72-14.19-65.05-28.48
Purchase of Investments-1,210.63-355.66-532.27-793.91-551.14-389.47-228.90-140.49-77.00
Sale Or Maturity of Investments594.21574.45700.34682.35258.03144.75214.7175.4448.52
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-617.43218.00165.00-117.17-296.00-246.77-16.82-66.29-28.99
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock948.22117.1112.13353.52278.47447.54102.5427.52103.14
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock948.22117.1112.13353.52278.47447.54102.5427.52103.14
Proceedsfrom Stock Options941.20112.1512.08353.490.00447.28102.4627.40102.85
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00-16.740.008.45
Change in Long Term Debt0.000.000.000.000.000.00-16.740.008.45
Issuance of Long Term Debt0.000.000.000.000.000.000.000.008.45
Reduction of Long Term Debt0.000.000.000.000.000.00-16.740.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities948.22117.1112.13353.52278.47447.5485.8027.52111.59
Exchange Rate Effect-0.040.46-1.670.38-2.48-0.59-0.590.41-0.61
Net Change in Cash-20.0456.45-5.9391.40-118.45130.6820.25-43.0047.27
Free Cash Flow-351.79-279.92-184.46-150.94-101.32-71.55-50.76-5.87-35.23
Preferred Dividends (Cash Flow)-0.000.000.00-----
Deferred Taxes & Investment Tax Credit--3.20-8.86-0.29-0.040.06-0.29-0.13-0.11

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments950.80930.691,094.75548.89462.27487.55
Short Term Receivables1.171.631.171.370.811.10
Inventories0.000.000.000.000.000.00
Other Current Assets8.1013.5510.7210.3917.0611.61
Total Current Assets960.07945.871,106.63560.65480.14500.25
Net Property, Plant & Equipment12.5213.1614.5815.3515.8516.50
Total Investments and Advances202.68314.41244.8737.1592.99137.30
Intangible Assets-0.000.000.000.000.00
Deferred Tax Assets15.4614.3612.42361.3711.7511.05
Other Assets9.157.978.307.157.119.19
Total Assets1,199.881,295.771,386.81981.67607.84674.28
Short Term Debt Incl. Current Port. of LT Debt1.151.341.561.531.501.46
Accounts Payable1.932.485.753.884.554.79
Income Tax Payable0.110.940.270.310.23-
Other Current Liabilities42.1240.2532.2436.0632.0526.80
Total Current Liabilities45.3045.0139.8141.7938.3433.05
Long Term Debt4.865.085.936.416.837.26
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---348.51--
Other Liabilities3.333.293.253.203.160.00
Total Liabilities53.4953.3848.99399.9148.3340.30
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,146.381,242.401,337.82581.76559.51633.98
Total Shareholders Equity1,146.381,242.401,337.82581.76559.51633.98
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,146.381,242.401,337.82581.76559.51633.98
Total Liabilities & Stockholders Equity1,199.881,295.771,386.81981.67607.84674.28
Book Value Per Share11.6712.8413.857.277.268.24
Tangible Book Value Per Share11.6712.8413.857.277.268.24
Full-Time Employees---370--
Price to Book Ratio3.554.368.006.184.873.41
Return on Assets-47.43-41.54-35.98-33.77-42.44-35.71
Return on Equity-50.27-43.62-37.53-51.76-45.14-37.65
Return on Invested Capital-9.59-8.88-7.61-17.90-16.05-13.21
Quick Ratio21.1921.0227.7913.4212.5215.14
Current Ratio21.1921.0227.7913.4212.5215.14

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-108.06-109.75-102.30-102.29-91.95-87.35
Depreciation0.550.550.590.590.650.65
Other Funds (Non Cash)15.3614.1615.7514.7114.3817.98
Funds from Operations-93.23-96.97-85.52-88.08-77.63-68.91
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.902.44-3.389.055.062.45
Cash from Operating Activities-88.33-94.53-88.90-79.03-72.57-66.45
Capital Expenditures-0.28-0.27-0.13-0.31-0.28-0.16
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments57.17-327.53-407.1561.0839.1484.48
Purchase of Investments-162.11-485.75-505.65-57.12-75.35-92.70
Sale Or Maturity of Investments219.28158.2298.50118.20114.49177.17
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities56.89-327.80-407.2860.7738.8684.32
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-4.63-3.89843.01113.732.390.09
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-4.63-3.89843.01113.732.390.09
Proceedsfrom Stock Options-4.82-3.89837.53112.390.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-4.63-3.89843.01113.732.390.09
Exchange Rate Effect-0.060.26-0.13-0.11-0.010.64
Net Change in Cash-36.12-425.97346.7095.35-31.3218.59
Free Cash Flow-88.61-94.81-89.03-79.34-72.85-66.61

Revenue breakdown

Pharmaceutical Preparations2025: 7.50M
Canada2025: 7.50M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.03%7.4M91.7M1.50M
2026-10-158.01%7.3M91.7M1.43M
2026-09-306.58%6.0M91.8M1.41M
2026-09-157.02%6.4M91.8M1.08M
2026-08-316.91%6.3M91.8M1.22M
2026-08-146.18%5.7M91.8M1.33M
2026-07-315.94%5.4M90.7M1.38M
2026-07-156.98%6.3M90.8M1.42M
2026-06-306.89%6.3M90.8M1.28M
2026-06-154.86%4.4M90.8M1.17M
2026-05-294.46%4.0M90.7M1.47M
2026-05-154.23%3.8M90.7M1.40M
2026-04-304.48%4.1M92.7M1.37M
2026-04-155.24%4.9M92.7M1.37M
2026-03-315.27%4.9M92.1M1.42M
2026-03-136.79%5.5M80.3M1.30M
2026-02-276.89%5.5M80.3M867.58K
2026-02-137.22%5.4M74.6M868.42K
2026-01-307.41%5.5M74.8M878.43K
2026-01-157.18%5.4M74.8M869.01K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call20.000.000.000.00-0.000.00---
call22.500.000.000.00-0.000.00---
call25.000.000.000.00-0.000.00---
call27.500.000.000.00-0.000.00---
call30.000.000.008.40-0.000.00---
call32.500.000.008.06-2.000.00---
call35.000.000.006.35-41.000.00---
call37.500.000.003.80-1240.00---
call40.000.000.002.19-1,8970.00---
call42.500.000.001.00-2170.00---
call45.000.000.000.40-1550.00---
call47.500.000.000.45-6.000.00---
call50.000.000.000.02-52.000.00---
call52.500.000.000.00-0.000.00---
call55.000.000.000.00-0.000.00---
call57.500.000.000.00-0.000.00---
call60.000.000.000.00-0.000.00---
call62.500.000.000.00-0.000.00---
call65.000.000.000.00-70.000.00---
call70.000.000.000.00-1.000.00---
call75.000.000.000.00-0.000.00---
call80.000.000.000.00-0.000.00---
call85.000.000.000.95-1.000.00---
put20.000.000.000.00-0.000.00---
put22.500.000.000.00-0.000.00---
put25.000.000.000.84-16.000.00---
put27.500.000.000.36-1040.00---
put30.000.000.000.18-1070.00---
put32.500.000.000.40-23.000.00---
put35.000.000.001.08-49.000.00---
put37.500.000.000.50-64.000.00---
put40.000.000.000.90-79.000.00---
put42.500.000.007.24-5.000.00---
put45.000.000.000.00-1.000.00---
put47.500.000.000.00-1.000.00---
put50.000.000.000.00-0.000.00---
put52.500.000.000.00-0.000.00---
put55.000.000.000.00-0.000.00---
put57.500.000.000.00-0.000.00---
put60.000.000.000.00-0.000.00---
put62.500.000.000.00-0.000.00---
put65.000.000.000.00-0.000.00---
put70.000.000.000.00-0.000.00---
put75.000.000.000.00-0.000.00---
put80.000.000.000.00-0.000.00---
put85.000.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-06SCHEDULE 13G/ASEC
2026-11-06SCHEDULE 13GSEC
2026-11-05SCHEDULE 13G/ASEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-314Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-28144Filing for proposed sale of securities under Rule 144.SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-07SCHEDULE 13G/ASEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-06SCHEDULE 13G/ASEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-05144Filing for proposed sale of securities under Rule 144.SEC
2026-06-05144Filing for proposed sale of securities under Rule 144.SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-091.68M200
2026-08001.07M2
2026-070000
2026-0600133.49K2
2026-050000
2026-040000
2026-030017.85M7
2026-020000
2026-01001.78M1
2025-12001.14M2
2025-11004.37K1

Institutional holders

Manager% owned
FMR LLC11.93%
BlackRock, Inc.7.78%
Avoro Capital Advisors LLC5.98%
Polar Capital Holdings Plc4.73%
DRIEHAUS CAPITAL MANAGEMENT LLC4.57%
Jupiter Topco LLC4.33%
PRICE T ROWE ASSOCIATES INC /MD/3.36%
JPMORGAN CHASE & CO2.71%
Capital International Investors2.44%
T. Rowe Price Investment Management, Inc.2.24%

Funds

Fund% owned
SMALLCAP World Fund Inc3.23%
Strategic Advisers Fidelity U.S. Total Stock Fund2.81%
VANGUARD HEALTH CARE FUND2.80%
iShares Russell 2000 ETF2.61%
T. Rowe Price Capital Appreciation Fund1.32%
Fidelity Small Cap Index Fund1.11%
JPMorgan Mid Cap Growth Fund1.00%
iShares Russell 2000 Growth ETF0.94%
T. Rowe Price New Horizons Fund, Inc.0.93%
Select Health Care Portfolio0.89%

OakChart. XENE. Cached 15 minutes.